Fleury (FLRY3) Stock Overview
Provides diagnostic imaging, clinical analysis, fertility, and infusions services in Brazil. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
FLRY3 Community Fair Values
Create NarrativeSee what 15 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Fleury S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | R$15.60 |
| 52 Week High | R$18.10 |
| 52 Week Low | R$12.16 |
| Beta | 0.32 |
| 1 Month Change | -6.31% |
| 3 Month Change | -10.96% |
| 1 Year Change | 24.30% |
| 3 Year Change | -2.44% |
| 5 Year Change | -39.82% |
| Change since IPO | 79.51% |
Recent News & Updates
Narrative Update • Apr 22
FLRY3: Fair View Will Reflect Brazil Meeting Decisions And Updated Assumptions
Analysts have modestly raised their price target for Fleury to R$17.45 from R$17.22, citing updated assumptions that now reflect slightly different discount rates, revenue growth, profit margins and future P/E expectations. What's in the News Fleury has scheduled a Special and Extraordinary Shareholders Meeting for April 13, 2026, with the session set to be held exclusively in Brazil (Key Developments).
Narrative Update • Apr 07
FLRY3: Special Meeting Will Highlight Overvaluation Risks Despite Minor Assumption Tweaks
Analysts have kept Fleury's R$14.40 price target effectively unchanged, citing only slight adjustments to revenue growth, profit margin and forward P/E assumptions that leave their overall view largely intact. What's in the News Fleury has scheduled a Special and Extraordinary Shareholders Meeting for April 13, 2026, to be held exclusively in Brazil.Narrative Update • Mar 24
FLRY3: Revised Assumptions Suggest Fair Pricing With Limited Upside Ahead
Analysts have slightly raised their price target on Fleury to R$14.40 from R$14.25, citing updated assumptions that keep the discount rate steady while trimming revenue growth expectations and modestly adjusting profit margin and future P/E inputs. What's in the News Fleury has scheduled a Special and Extraordinary Shareholders Meeting for April 13, 2026, which will be held exclusively in Brazil (Key Developments).Recent updates
Narrative Update • Apr 22
FLRY3: Fair View Will Reflect Brazil Meeting Decisions And Updated Assumptions
Analysts have modestly raised their price target for Fleury to R$17.45 from R$17.22, citing updated assumptions that now reflect slightly different discount rates, revenue growth, profit margins and future P/E expectations. What's in the News Fleury has scheduled a Special and Extraordinary Shareholders Meeting for April 13, 2026, with the session set to be held exclusively in Brazil (Key Developments).Narrative Update • Apr 07
FLRY3: Special Meeting Will Highlight Overvaluation Risks Despite Minor Assumption Tweaks
Analysts have kept Fleury's R$14.40 price target effectively unchanged, citing only slight adjustments to revenue growth, profit margin and forward P/E assumptions that leave their overall view largely intact. What's in the News Fleury has scheduled a Special and Extraordinary Shareholders Meeting for April 13, 2026, to be held exclusively in Brazil.Narrative Update • Mar 24
FLRY3: Revised Assumptions Suggest Fair Pricing With Limited Upside Ahead
Analysts have slightly raised their price target on Fleury to R$14.40 from R$14.25, citing updated assumptions that keep the discount rate steady while trimming revenue growth expectations and modestly adjusting profit margin and future P/E inputs. What's in the News Fleury has scheduled a Special and Extraordinary Shareholders Meeting for April 13, 2026, which will be held exclusively in Brazil (Key Developments).Narrative Update • Mar 10
FLRY3: Slight Assumption Tweaks Will Still Limit Future Upside Potential
Analysts have nudged their price target on Fleury slightly higher to R$14.25, reflecting small adjustments to revenue growth, profit margin assumptions, and future P/E expectations. Valuation Changes Fair Value: R$14.25 remains effectively unchanged, with only a minimal rounding adjustment in the model output.Narrative Update • Feb 23
FLRY3: Investor Day Plans Will Still Offer Limited Upside Potential
Analysts have slightly adjusted their view on Fleury, with the implied fair value holding at about R$14.25. Small tweaks to revenue growth, profit margin and future P/E assumptions reflect a marginally refined outlook rather than a major change in direction.Narrative Update • Feb 09
FLRY3: Higher Assumed Profitability Will Still Point To Limited Upside
The analyst fair value estimate for Fleury has moved from approximately R$12.50 to around R$14.25 per share. Analysts cite updated assumptions around the discount rate, revenue growth, profit margin and future P/E as the key drivers behind this change.Analysis Article • Jan 28
Fleury S.A.'s (BVMF:FLRY3) Price Is Out Of Tune With Earnings
Fleury S.A.'s ( BVMF:FLRY3 ) price-to-earnings (or "P/E") ratio of 15.4x might make it look like a strong sell right...Narrative Update • Jan 26
FLRY3: Fair View Will Reflect Investor Day Focus And Governance Decisions
Analysts have nudged their fair value estimate for Fleury from R$16.67 to about R$17.22, reflecting updated assumptions around slightly higher revenue growth, improved profit margins and a modestly lower future P/E multiple. What's in the News Fleury has scheduled its 2025 Investor Day, giving you a dedicated forum to hear management discuss the business, capital allocation, and long term priorities in more depth (Key Developments).Narrative Update • Jan 12
FLRY3: Fair View Will Balance Investor Day Outlook And Governance Decisions
Analysts have adjusted their price target for Fleury to roughly $16.67 per share, reflecting updated views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News Fleury has scheduled its 2025 Investor Day, giving you a set date to hear management discuss the business, capital allocation, and long term priorities in more depth (Key Developments).Analysis Article • Jan 07
Does Fleury (BVMF:FLRY3) Have A Healthy Balance Sheet?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Analysis Article • Nov 16
Investors Can Find Comfort In Fleury's (BVMF:FLRY3) Earnings Quality
Fleury S.A.'s ( BVMF:FLRY3 ) stock was strong despite it releasing a soft earnings report last week. We think that...Analysis Article • Oct 22
Fleury S.A. (BVMF:FLRY3) Investors Are Less Pessimistic Than Expected
Fleury S.A.'s ( BVMF:FLRY3 ) price-to-earnings (or "P/E") ratio of 13.4x might make it look like a sell right now...Analysis Article • Sep 24
Fleury (BVMF:FLRY3) Has A Pretty Healthy Balance Sheet
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Narrative Update • Sep 23
Digital Investments And Demographics Will Transform Diagnostic Medicine
The increase in Fleury’s consensus price target to R$15.97 primarily reflects a modest rise in expected future earnings multiples, as indicated by the higher future P/E, with the fair value updated accordingly. Valuation Changes Summary of Valuation Changes for Fleury The Consensus Analyst Price Target has risen slightly from R$15.27 to R$15.97.Analysis Article • Jun 19
Investor Optimism Abounds Fleury S.A. (BVMF:FLRY3) But Growth Is Lacking
With a price-to-earnings (or "P/E") ratio of 11.7x Fleury S.A. ( BVMF:FLRY3 ) may be sending bearish signals at the...Analysis Article • May 17
Fleury's (BVMF:FLRY3) Solid Earnings Are Supported By Other Strong Factors
The subdued stock price reaction suggests that Fleury S.A.'s ( BVMF:FLRY3 ) strong earnings didn't offer any surprises...Analysis Article • Apr 15
Does Fleury (BVMF:FLRY3) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysis Article • Mar 02
Analysts Have Been Trimming Their Fleury S.A. (BVMF:FLRY3) Price Target After Its Latest Report
Shareholders might have noticed that Fleury S.A. ( BVMF:FLRY3 ) filed its yearly result this time last week. The early...
New Narrative • Feb 24
Digital Transformation And Pardini Integration Will Improve Efficiency And Capture Niche Markets
Expansion into specialized integrated centers and mobile services could drive revenue growth and improve margins without substantial capital expenditure.Analysis Article • Dec 15
Fleury's (BVMF:FLRY3) Dividend Is Being Reduced To R$0.2139
Fleury S.A.'s ( BVMF:FLRY3 ) dividend is being reduced from last year's payment covering the same period to R$0.2139 on...Analysis Article • Nov 15
We Think Fleury's (BVMF:FLRY3) Profit Is Only A Baseline For What They Can Achieve
Fleury S.A. ( BVMF:FLRY3 ) just reported healthy earnings but the stock price didn't move much. We think that investors...Analysis Article • Nov 02
Fleury (BVMF:FLRY3) Seems To Use Debt Quite Sensibly
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysis Article • Sep 26
Fleury S.A.'s (BVMF:FLRY3) Price Is Out Of Tune With Earnings
Fleury S.A.'s ( BVMF:FLRY3 ) price-to-earnings (or "P/E") ratio of 14.5x might make it look like a sell right now...Analysis Article • Jun 18
We Think Fleury (BVMF:FLRY3) Can Stay On Top Of Its Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysis Article • Apr 16
The Price Is Right For Fleury S.A. (BVMF:FLRY3)
Fleury S.A.'s ( BVMF:FLRY3 ) price-to-earnings (or "P/E") ratio of 18.4x might make it look like a strong sell right...Analysis Article • Mar 14
Concerns Surrounding Fleury's (BVMF:FLRY3) Performance
The recent earnings posted by Fleury S.A. ( BVMF:FLRY3 ) were solid, but the stock didn't move as much as we expected...Analysis Article • Jan 05
Earnings Tell The Story For Fleury S.A. (BVMF:FLRY3)
Fleury S.A.'s ( BVMF:FLRY3 ) price-to-earnings (or "P/E") ratio of 25.5x might make it look like a strong sell right...Analysis Article • Oct 05
Fleury (BVMF:FLRY3) Has A Pretty Healthy Balance Sheet
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analysis Article • Jun 27
Does Fleury (BVMF:FLRY3) Have A Healthy Balance Sheet?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analysis Article • Feb 25
We Think Fleury (BVMF:FLRY3) Can Stay On Top Of Its Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysis Article • Sep 26
At R$18.27, Is It Time To Put Fleury S.A. (BVMF:FLRY3) On Your Watch List?
Fleury S.A. ( BVMF:FLRY3 ), is not the largest company out there, but it received a lot of attention from a substantial...Analysis Article • Sep 08
Does Fleury (BVMF:FLRY3) Have A Healthy Balance Sheet?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analysis Article • Jul 01
Fleury (BVMF:FLRY3) Has Some Way To Go To Become A Multi-Bagger
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? One common approach...Analysis Article • Jun 10
When Should You Buy Fleury S.A. (BVMF:FLRY3)?
Fleury S.A. ( BVMF:FLRY3 ), is not the largest company out there, but it saw a decent share price growth in the teens...Analysis Article • Apr 10
Is Fleury (BVMF:FLRY3) Using Too Much Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysis Article • Mar 24
Return Trends At Fleury (BVMF:FLRY3) Aren't Appealing
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Typically, we'll...Shareholder Returns
| FLRY3 | BR Healthcare | BR Market | |
|---|---|---|---|
| 7D | -5.9% | -7.7% | -4.0% |
| 1Y | 24.3% | -12.7% | 13.3% |
Return vs Industry: FLRY3 exceeded the BR Healthcare industry which returned -12.7% over the past year.
Return vs Market: FLRY3 exceeded the BR Market which returned 13.3% over the past year.
Price Volatility
| FLRY3 volatility | |
|---|---|
| FLRY3 Average Weekly Movement | 4.0% |
| Healthcare Industry Average Movement | 10.4% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in BR Market | 8.1% |
| 10% least volatile stocks in BR Market | 1.9% |
Stable Share Price: FLRY3 has not had significant price volatility in the past 3 months compared to the BR market.
Volatility Over Time: FLRY3's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1926 | 28,000 | Jeane Tsutsui | ri.fleury.com.br |
Fleury S.A., together with its subsidiaries, provides diagnostic imaging, clinical analysis, fertility, and infusions services in Brazil. It operates in two segments, Diagnostic Medicine and Integrated Medicine. The company also provides health management services, such as telemedicine; orthopedic medicine services; laboratory support; toxicological exam; preventive, integrated solutions, and clinical research in oncology; integrated solutions, research, development of processes and services in genomics; and laboratory analysis services.
Fleury S.A. Fundamentals Summary
| FLRY3 fundamental statistics | |
|---|---|
| Market cap | R$8.50b |
| Earnings (TTM) | R$634.76m |
| Revenue (TTM) | R$8.50b |
13.4x
P/E Ratio1.0x
P/S RatioIs FLRY3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FLRY3 income statement (TTM) | |
|---|---|
| Revenue | R$8.50b |
| Cost of Revenue | R$6.24b |
| Gross Profit | R$2.26b |
| Other Expenses | R$1.63b |
| Earnings | R$634.76m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Aug 06, 2026
| Earnings per share (EPS) | 1.16 |
| Gross Margin | 26.61% |
| Net Profit Margin | 7.47% |
| Debt/Equity Ratio | 78.4% |
How did FLRY3 perform over the long term?
See historical performance and comparisonDividends
7.8%
Current Dividend Yield108%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/17 13:23 |
| End of Day Share Price | 2026/05/15 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Fleury S.A. is covered by 19 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Flavio Yoshida | BofA Global Research |
| Marcio Osako | Bradesco S.A. Corretora de Títulos e Valores Mobiliários |
| Carlos Palhares Sequeira | BTG Pactual |